ImmuSAFE enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination.
These results will provide critical insights on whether individuals have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or whether booster vaccinations are required.
ImmuSAFE COVID+ will also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.
ImmuSAFE is a lab-based biochip test that utilises Sengenics' patented KREX protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites.
The test contains more than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions.
Cross-reactivity between immunogenic regions of SARS-CoV-2 and other coronaviruses may lead to an overestimation of sero-prevalence in a given population.
ImmuSAFE is designed to reduce cross-reactivity by targeting multiple SARS-CoV-2 specific domains, resulting in fewer false positives, and a more accurate determination of sero-prevalence.
The ImmuSAFE product range also includes other biochip-based tests that incorporate additional viral antigens such as: SARS-CoV-2 Envelope, Nucleocapsid proteins from 13 other Coronaviruses including five human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes.
Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.
Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs).
KREX can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests.
Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial